Cadence Pharmaceuticals — Investor Presentation (January 2012)
29 slides from Cadence Pharmaceuticals's investor presentation, Jan 9, 2012
Slide 1: Corporate Overview
Corporate Overview Improving the lives of hospitalized patients January 2012 Exhibit 99.1
Slide 2: Caution on forward-looking statements
Caution on forward-looking statements CADENCE and OFIRMEV are trademarks of Cadence Pharmaceuticals, Inc. © 2011 Cadence Pharmaceuticals, Inc. All rights reserved. ® ® This presentation includes forward-looking statements, which are based on our current beliefs and expectations. Such statements incl
Slide 3: Company Highlights
Company Highlights Specialty biopharmaceutical company, focused on developing and commercializing proprietary therapeutics utilized in the hospital setting – Sustainable core business of OFIRMEV ® with opportunities to diversify product portfolio OFIRMEV - a differentiated, new class of IV pain medi
Slide 4: Overview of Cadence
Overview of Cadence IONSYS™ is a trademark of Incline Therapeutics, Inc. OFIRMEV ® (IV Acetaminophen) – U.S. and Canadian rights licensed from Bristol Myers Squibb – FDA approved in Nov. 2010 and commercially launched Jan. 2011 with broad indications for management of pain and fever – Established ho
Slide 5: OFIRMEV: product overview
OFIRMEV ® : product overview PERFALGAN™ is a trademark of Bristol Myers Squibb Company. OFIRMEV ® (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New class of IV medication • non-narcotic / opioid •
Slide 6: OFIRMEV: strong foundation for commercial success
OFIRMEV ® : * Clinical benefit of opioid reduction not demonstrated Effective Pain Control Experienced Hospital Sales Force Economic Value strong foundation for commercial success • Sales force average >10 years hospital selling experience • Extensive relationships, significant overlap with prior te
Slide 7: OFIRMEV: indication supports message
OFIRMEV ® : indication supports message Broad Indication • Mild to moderate pain • Moderate to severe pain with adjunctive opioids • Reduction of fever • Adults and children 2 and older Message • Significant pain relief • Reduced opioid consumption* • Improved patient satisfaction • Established safe
Slide 8: Limitations of other IV pain therapies
Limitations of other IV pain therapies Opioids NSAIDs Sedation Nausea Vomiting Constipation Headache Cognitive impairment Respiratory depression Black Box Warning Bleeding GI complications Kidney complications Cardiovascular risks Prolonged recovery Increased length of stay Higher costs to the insti
Slide 9: Multi-modal analgesia: current US and EU approaches
Pain Intensity Current US Approach Current EU Approach Multi-modal analgesia: Severe Opioids IV acetaminophen + opioids Moderate Opioids IV acetaminophen +/- opioids* Mild Opioids IV acetaminophen the norms * First post-operative analgesic drug, then add opioids if necessary
Slide 10: Sinatra Study: pivotal acute pain clinical trial
Sinatra Study: IV acetaminophen placebo p-value Sinatra, et al. Anesthesiology, V 102, No. 4, April 2005. placebo IV acetaminophen Placebo-controlled, total hip or total knee replacement (n=49/52) p<0.001 . . pivotal acute pain clinical trial * Post hoc analysis based on currently acceptable regulat
Slide 11: Consistent opioid reduction across studies
Consistent opioid reduction across studies Pain Intensity Opioid Reduction* Time p Value *Reduction in number of patients requiring analgesic rescue with ketorolac and fentanyl 1) Sinatra, et all.,2005; 2) Memis, et al., 2005; 3) Viscusi, et al., 2005; 4) Hong, et a., 2010 5) Atef, et al., 2008 Seve
Slide 12: OFIRMEV: economic value
OFIRMEV ® : economic value Placebo-controlled studies using IV acetaminophen demonstrated results that may be associated with possible hospital cost savings: – Decreased opioid consumption * • Total hip/knee replacement (1) • Total hip replacement (2, 3) • Adult tonsillectomy (4) • Endoscopic thyroi
Slide 13: The UK experience
The UK experience UK treatment paradigms for moderate and acute pain are similar to those in the US – Higher opioid than NSAID usage – Multimodal pain therapy Perfalgan, BMY’s IV acetaminophen – Launched in 2004 – Most share taken from opioids, some from NSAIDS Used alone and in combination with opi
Slide 14: Oral opioids: acetaminophen combinations dominate
Oral opioids: acetaminophen combinations dominate Opioid-acetaminophen combinations Opioid-only products Opioid-NSAID combinations 74% 25% 1% Source: IMS data, 2008. 74% of oral opioid doses sold in U.S. contain acetaminophen Approximately 14.4 billion total doses sold in 2008 Acetaminophen + hydroc
Slide 15: Hospital products: multi-step launch process
Hospital products: Regulatory Approval Physician Access Formulary Access Sales multi-step launch process
Slide 16: OFIRMEV: adoption process
Stage III Increase Doses Per Patient Stage II Broaden Physician Utilization Stage I Create Access OFIRMEV ® : adoption process
Slide 17: OFIRMEV: strong early launch indicators
OFIRMEV ® : strong early launch indicators Rapid formulary adoption – On formulary in approx. 1,580 hospitals* – Mix of formulary wins is representative of overall target market – Includes major academic medical centers and large community healthcare systems Most hospitals approved OFIRMEV with mini
Slide 18: Revenue growth: three main drivers
Revenue growth: three main drivers Growth in customer base – Number of unique customer accounts in Q4 increased 23% from Q3 to 2,200+ Increase in frequency of product use – ~1,600 of 2,200 hospitals reordered product through end of Q4 Increase in average quantity of product order per customer – Cust
Slide 19: Rapid Formulary Penetration
Rapid Formulary Penetration Formulary approvals have exceeded Company projections through Q4 – Approx. 1,580 hospital formulary approvals achieved through December 31, Source: Cadence Internal Data
Slide 20: Significant Sales Growth Through Q4
Significant Sales Growth Through Q4 OFIRMEV sales continue to accelerate • Q4 sales exceeded cumulative sales during st months of Source: Wolters Kluwer Pharma Solutions, Source® PHAST Institution. *December sales estimate derived from Cadence internal data.
Slide 21: Significant Growth in New Customers
Significant Growth in New Customers Significant growth in new and repeat customers each quarter 23% growth in unique accounts ordering OFIRMEV ® in Q4 33% increase in accounts that placed multiple orders in Q4
Slide 22: Growing demand: consistent order frequency growth
Growing demand: consistent order frequency growth (est.)
Slide 23: Growing demand: average order size growing steadily
Growing demand: average order size growing steadily Note: Sales data as reported through 12/22/12
Slide 24: Surgery penetration: deepening penetration of a growing base of hospitals
Surgery penetration: deepening penetration of a growing base of hospitals * Assumptions: # Patients Treated in On-Formulary Accts = Vial Sales in On-Formulary Accts ÷ 2.5 vials/patient Estimated U.S. Surgical Procedures = 30MM hospital-based surgical procedures/yr. Estimated Procedures in On-Formula
Slide 25: OFIRMEV: vial sales off to strong start
OFIRMEV ® : vial sales off to strong start * # of doses are shown for Entereg and Dificid, which are oral products ** Cubicin monthly sales are averaged within each quarter OFIRMEV vs Avg: 7.8X OFIRMEV Rank: Source: Wolters Kluwer Pharma Solutions, Source® PHAST Institution. Cubist Pharmaceuticals,
Slide 26: OFIRMEV: strong revenue ramp
OFIRMEV ® : strong revenue ramp ** Cubicin monthly sales are averaged within each quarter OFIRMEV hospital sales growth compares favorably vs. recent launches despite significantly lower price. Source: Wolters Kluwer Pharma Solutions, Source® PHAST Institution. Cubist Pharmaceuticals, Inc. Form 10-Q
Slide 27: Experienced Management & Commercial Team
Experienced Management & Commercial Team CEO > 25 years CFO > 25 years CMO > 25 years Commercial Team CCO > 15 years commercial management experience VP Sales > 25 years sales management experience 3 Regional Business Directors: – Avg. 21 years industry experience, 13 years hospital sales management
Slide 28: Company Highlights
Company Highlights Specialty biopharmaceutical company, focused on developing and commercializing proprietary therapeutics utilized in the hospital setting – Sustainable core business of OFIRMEV ® with opportunities to diversify product portfolio OFIRMEV - a differentiated, new class of IV pain medi
Slide 29: Cadence: financial position
Cadence: financial position 12 Months Ended 12/31/10 (MM) 9 Months Ended 9/30/11 (MM) Net Product Revenue $ 0.0 $ 5.6 Operating expenses $ 54.9 $ 68.0 Cash, cash equivalents & short-term investments $134.1 $145.0 (1) Shares outstanding 63.1 63.6 (1) Pro forma cash including net proceeds of $77.3MM r
Cadence Pharmaceuticals — Investor Presentation (January 2012) on 6ix